{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:43:52Z","timestamp":1792215832860,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinre.2026.102887","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:13:17Z","timestamp":1785341597000},"page":"102887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Squamous cell anal carcinoma: Current therapeutic approaches"],"prefix":"10.1016","volume":"50","author":[{"given":"Valentina","family":"Zen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Intini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-1171","authenticated-orcid":false,"given":"Giulia","family":"Maddalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-4653","authenticated-orcid":false,"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2026.102887_bib0001","doi-asserted-by":"crossref","DOI":"10.5493\/wjem.v14.i3.98525","article-title":"Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment","volume":"14","author":"English","year":"2024","journal-title":"World J Exp Med"},{"issue":"8","key":"10.1016\/j.clinre.2026.102887_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/cancers17081289","article-title":"Advances in the management, treatment, and surveillance of anal squamous cell cancer","volume":"17","author":"Araradian","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clinre.2026.102887_bib0003","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clinre.2026.102887_bib0004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1071\/SH12070","article-title":"The epidemiology of anal cancer","volume":"9","author":"Grulich","year":"2012","journal-title":"Sex Health"},{"issue":"5","key":"10.1016\/j.clinre.2026.102887_bib0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.currproblcancer.2018.11.001","article-title":"Squamous cell carcinoma of the anal canal","volume":"42","author":"Morton","year":"2018","journal-title":"Curr Probl Cancer"},{"issue":"9","key":"10.1016\/j.clinre.2026.102887_bib0006","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bjs.4994","article-title":"Malignant transformation of high-grade anal intraepithelial neoplasia","volume":"92","author":"Scholefield","year":"2005","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.clinre.2026.102887_bib0007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1445-2197.2006.03837.x","article-title":"Malignant progression of anal intra-epithelial neoplasia","volume":"76","author":"Watson","year":"2006","journal-title":"ANZ J Surg"},{"issue":"2","key":"10.1016\/j.clinre.2026.102887_bib0008","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4251\/wjgo.v9.i2.50","article-title":"Anal intraepithelial neoplasia: a review of diagnosis and management","volume":"9","author":"Roberts","year":"2017","journal-title":"World J Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102887_bib0009","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1473-3099(19)30164-1","article-title":"Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis","volume":"19","author":"Lin","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.clinre.2026.102887_bib0010","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s10147-023-02340-y","article-title":"Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body","volume":"28","author":"Egawa","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clinre.2026.102887_bib0011","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinre.2026.102887_bib0012","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.2015-0091","article-title":"Clinicopathologic features associated with human Papillomavirus\/p16 in patients with metastatic squamous cell carcinoma of the anal canal","volume":"20","author":"Morris","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clinre.2026.102887_bib0013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13027-024-00624-0","article-title":"Prevalence of HPV in anal cancer: exploring the role of infection and inflammation","volume":"19","author":"Ebrahimi","year":"2024","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"10.1016\/j.clinre.2026.102887_bib0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0016","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1470-2045(07)70043-8","article-title":"Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study","volume":"8","author":"Edgren","year":"2007","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102887_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1055-9965.EPI-19-0601","article-title":"Risk of anal cancer following benign anal disease and anal cancer precursor lesions: a danish nationwide cohort study","volume":"29","author":"Faber","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"10.1016\/j.clinre.2026.102887_bib0018","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/DCR.0000000000001219","article-title":"What is the risk of anal carcinoma in patients with anal intraepithelial neoplasia III?","volume":"61","author":"Lee","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"24","key":"10.1016\/j.clinre.2026.102887_bib0019","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","article-title":"Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer","volume":"386","author":"Palefsky","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clinre.2026.102887_bib0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102887_bib0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"issue":"36","key":"10.1016\/j.clinre.2026.102887_bib0022","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.3748\/wjg.v20.i36.13052","article-title":"Anal squamous cell carcinoma: an evolution in disease and management","volume":"20","author":"Osborne","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0023","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clinre.2026.102887_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.6004\/jnccn.2023.0030","article-title":"Anal carcinoma, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.clinre.2026.102887_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-109655","article-title":"Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial","volume":"15","author":"Frood","year":"2025","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.clinre.2026.102887_bib0026","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102887_bib0027","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.clinre.2026.102887_bib0028","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102887_bib0029","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clinre.2026.102887_bib0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clinre.2026.102887_bib0031","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102887_bib0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2012.06.006","article-title":"Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin","volume":"104","author":"Sebag-Montefiore","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clinre.2026.102887_bib0033","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/CMAR.S331429","article-title":"Metastatic or locally recurrent anal squamous cell carcinoma (SCAC): current clinical trial landscape and novel approaches","volume":"14","author":"Rogers","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.clinre.2026.102887_bib0034","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS malignancy consortium trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102887_bib0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II eastern cooperative oncology group-american college of radiology imaging network cancer research group trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clinre.2026.102887_bib0036","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3390\/healthcare11233010","article-title":"Recent advances in the management of anal cancer","volume":"11","author":"Upadhyay","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.clinre.2026.102887_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amsu.2020.04.016","article-title":"Squamous cell anal cancer: Management and therapeutic options","volume":"55","author":"Pessia","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"issue":"7","key":"10.1016\/j.clinre.2026.102887_bib0038","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/DCR.0000000000001114","article-title":"The american society of colon and rectal surgeons clinical practice guidelines for anal squamous cell cancers (Revised 2018)","volume":"61","author":"Stewart","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"1\u20132","key":"10.1016\/j.clinre.2026.102887_bib0039","first-page":"5","article-title":"Metastatic anal cancer: the search for cure","volume":"29","author":"Cummings","year":"2006","journal-title":"Onkologie"},{"issue":"1","key":"10.1016\/j.clinre.2026.102887_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2018.7085","article-title":"Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer","volume":"17","author":"Wang","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clinre.2026.102887_bib0041","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.3390\/curroncol30050343","article-title":"Immunotherapy in anal cancer","volume":"30","author":"Dhawan","year":"2023","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102887_bib0042","first-page":"861","article-title":"[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"issue":"22","key":"10.1016\/j.clinre.2026.102887_bib0043","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102887_bib0044","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102887_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40164-023-00413-2","article-title":"DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study","volume":"12","author":"Kim","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0046","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.clinre.2026.102887_bib0047","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2026.102887_bib0048","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"15_suppl","key":"10.1016\/j.clinre.2026.102887_bib0049","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.clinre.2026.102887_bib0051","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO-25-00929","article-title":"NCI9673 (Part B): ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal","volume":"44","author":"Morris","year":"2026","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clinre.2026.102887_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.clinre.2026.102887_bib0053","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","article-title":"Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status","volume":"77","author":"Lukan","year":"2009","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.clinre.2026.102887_bib0054","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/1078-0432.CCR-24-1512","article-title":"Phase II trial of atezolizumab and bevacizumab for treatment of HPV-positive unresectable or metastatic squamous cell carcinoma of the anal canal","volume":"31","author":"Morris","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clinre.2026.102887_bib0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study","volume":"25","author":"Kim","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10495","key":"10.1016\/j.clinre.2026.102887_bib0056","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:18:20Z","timestamp":1792214300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2210740126001336"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102887","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Squamous cell anal carcinoma: Current therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102887"}}